Advertisement

Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population

  • Theresa H. Nguyen
  • Niharika Mallepally
  • Tariq Hammad
  • Yan Liu
  • Aaron P. Thrift
  • Hashem B. El-Serag
  • Mimi C. TanEmail author
Original Article

Abstract

Background

Helicobacter pylori infection is an established causal factor for non-cardia gastric cancer. H. pylori negative gastric cancer prevalence among US patients is unclear.

Methods

This retrospective cohort study examined H. pylori prevalence among consecutive patients with incident non-cardia gastric adenocarcinoma at the Houston VA Hospital (11/2007–10/2018). H. pylori positivity was defined by H. pylori on histopathology, positive antibody serology, stool antigen, or urea breath testing. We examined for trends in H. pylori negative gastric cancer based on year of diagnosis. Associations between histopathologic and cancer-related outcomes with H. pylori positivity were determined using regression models.

Results

Of 91 patients with gastric adenocarcinoma, most were men (N = 87, 95.6%), black (N = 47, 51.6%), with mean age at diagnosis of 68.0 years (SD 10.8). In addition to gastric cancer biopsy histopathology, 74 patients (81.3%) had ≥ 1 testing for H. pylori, including antibody serology (n = 34), non-cancer gastric biopsy histopathology (n = 63), or stool antigen (n = 1). The overall prevalence of H. pylori infection was 38.5% and 45.9% among patients with ≥ 2 H. pylori tests. The proportions of H. pylori positive gastric cancer decreased from 50.0% (2007–2010) to 43.4% (2011–2014) and 29.3% (2015–2018) (p = 0.096). Active/acute gastritis (adjOR 3.74), atrophic gastritis (adjOR 15.30), and gastric intestinal metaplasia (adjOR 3.65) were associated with H. pylori positive gastric cancer.

Discussion

The prevalence of H. pylori infection among patients with non-cardia gastric adenocarcinoma is relatively low (38.5–45.9%) and decreasing over time. This finding suggests there may be other important causal factors apart from H. pylori for gastric adenocarcinoma.

Keywords

Epidemiology Gastric cancer Gastric adenocarcinoma Helicobacter pylori Veterans affairs Prevalence 

Notes

Author’s contribution

(i) Mimi C. Tan, MD, MPH is guarantor of the article; (ii) Specific author contributions: THN collected and analyzed the data, designed the research study, wrote the paper, and contributed to the design of the study; NM and TH collected the data and contributed to the design of the study; YL analyzed the data and contributed to the design of the study; APT, HBE, MCT analyzed the data, designed the research study, wrote the paper, and contributed to the design of the study; (iii) All authors have approved the final version of the manuscript.

Funding

This work was supported in part by National Institutes of Health Grant P30 DK056338 (Study Design and Clinical Research Core), which supports the Texas Medical Center Digestive Diseases Center. This research was supported in part with resources at the VA HSR&D Center for Innovations in Quality, Effectiveness and Safety (#CIN 13-413), at the Michael E. DeBakey VA Medical Center, Houston, TX. The opinions expressed reflect those of the authors and not necessarily those of the Department of Veterans Affairs, the US government or Baylor College of Medicine.

Compliance with Ethical Standards

Conflicts of interest

The authors report no competing interests for this publication.

References

  1. 1.
    Ferlay J, Soerjomataram I, Ervik M. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer. Published 2013. Accessed January 2019.Google Scholar
  2. 2.
    Cancer IAfRo. Estimated age-standardized incidence rates in 2018, worldwide, both sexes, all ages. In: Globocan. International Agency for Research on Cancer; 2018.Google Scholar
  3. 3.
    IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Gastric Cancer Prevention 2014; No. January, Lyon, France.Google Scholar
  4. 4.
    Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487–490.CrossRefGoogle Scholar
  5. 5.
    Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev. 2016;25:16–27.CrossRefGoogle Scholar
  6. 6.
    Burucoa C, Axon A. Epidemiology of Helicobacter pylori infection. Helicobacter. 2017;22:e12403.CrossRefGoogle Scholar
  7. 7.
    Mitchell H, Katelaris P. Epidemiology, clinical impacts and current clinical management of Helicobacter pylori infection. Med J Aust. 2016;204:376–380.CrossRefGoogle Scholar
  8. 8.
    Lim SH, Kim N, Kwon JW, et al. Trends in the seroprevalence of Helicobacter pylori infection and its putative eradication rate over 18 years in Korea: a cross-sectional nationwide multicenter study. PLoS ONE. 2018;13:e0204762.CrossRefGoogle Scholar
  9. 9.
    Eom BW, Jung KW, Won YJ, Yang H, Kim YW. Trends in gastric cancer incidence according to the clinicopathological characteristics in Korea, 1999–2014. Cancer Res Treat Off J Korean Cancer Assoc. 2018;50:1343–1350.Google Scholar
  10. 10.
    Anderson WF, Rabkin CS, Turner N, Fraumeni JF Jr, Rosenberg PS, Camargo MC. The changing face of noncardia gastric cancer incidence among US Non-Hispanic whites. J Natl Cancer Inst. 2018;110:608–615.CrossRefGoogle Scholar
  11. 11.
    Uemera N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789.CrossRefGoogle Scholar
  12. 12.
    Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415–419.CrossRefGoogle Scholar
  13. 13.
    Ono S, Kato M, Suzuki M, et al. Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic, and serological atrophy. Digestion. 2012;86:59–65.CrossRefGoogle Scholar
  14. 14.
    Kim HJ, Kim N, Yoon H, et al. Comparison between resectable Helicobacter pylori-negative and -positive gastric cancers. Gut Liver. 2016;10:212–219.CrossRefGoogle Scholar
  15. 15.
    Marrelli D, Pedrazzani C, Berardi A, et al. Negative Helicobacter pylori status is associated with poor pronogosis in patients with gastric cancer. Cancer. 2009;115:2071–2080.CrossRefGoogle Scholar
  16. 16.
    Meimarakis G, Winter H, Assmann I, et al. Helicobacter pylori as a prognostic indicator after curative resection of gastric carcinoma: a prospective study. Lancet Oncol. 2006;7:211–222.CrossRefGoogle Scholar
  17. 17.
    Hooi J, Lai W, Ng W, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153:420–429.CrossRefGoogle Scholar
  18. 18.
    Graham D. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. World J Gastroenterol. 2014;20:5191–5204.CrossRefGoogle Scholar
  19. 19.
    Lui FH, Tuan B, Swenson SL, Wong RJ. Ethnic disparities in gastric cancer incidence and survival in the USA: an updated analysis of 1992–2009 SEER data. Dig Dis Sci. 2014;59:3027–3034.  https://doi.org/10.1007/s10620-014-3275-3.CrossRefPubMedGoogle Scholar
  20. 20.
    Wang Z, Graham DY, Khan A, et al. Incidence of gastric cancer in the USA during 1999 to 2013: a 50-state analysis. Int J Epidemiol. 2018;47:966–975.CrossRefGoogle Scholar
  21. 21.
    Kang H, Kim N, Park Y, et al. Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa. Dig Dis Sci. 2006;51:2310–2315.  https://doi.org/10.1007/s10620-006-9276-0.CrossRefPubMedGoogle Scholar
  22. 22.
    Palestro G, Pellicano R, Fronda GR, et al. Prevalence of Helicobacter pylori infection and intestinal metaplasia in subjects who had undergone surgery for gastric adenocarcinoma in Northwest Italy. World J Gastroenterol. 2005;11:7131–7135.CrossRefGoogle Scholar
  23. 23.
    Kim JH, Cheung DY. Must-have knowledge about the Helicobacter pylori-negative gastric cancer. Gut Liver. 2016;10:157–159.CrossRefGoogle Scholar
  24. 24.
    Shiota S, Thrift AP, Green L, et al. Clinical manifestations of Helicobacter pylori-negative gastritis. Clin Gastroenterol Hepatol. 2017;15:1037–1046.CrossRefGoogle Scholar
  25. 25.
    Nordenstedt H, Graham DY, Kramer JR, et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013;108:65–71.CrossRefGoogle Scholar
  26. 26.
    Yamamoto Y, Fujisaki J, Omae M, Hirasawa T, Igarashi M. Helicobacter pylori-negative gastric cancer: characteristics and endoscopic findings. Dig Endosc. 2015;27:551–561.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Section of Gastroenterology and Hepatology, Department of MedicineBaylor College of MedicineHoustonUSA
  2. 2.Section of Epidemiology and Population Sciences, Department of MedicineBaylor College of MedicineHoustonUSA
  3. 3.Dan L Duncan Comprehensive Cancer CenterBaylor College of MedicineHoustonUSA
  4. 4.Center for Innovations in Quality, Effectiveness and Safety (IQuESt)Michael E DeBakey Veterans Affairs Medical CenterHoustonUSA

Personalised recommendations